πŸ‡ΊπŸ‡Έ FDA
Patent

US 10744193

Immunogenic RSV polypeptides

granted A61KA61K2039/523A61K2039/54

Quick answer

US patent 10744193 (Immunogenic RSV polypeptides) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/523, A61K2039/54, A61K2039/55, A61K2039/555